210 related articles for article (PubMed ID: 24668132)
1. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
Yasuda S; Kachi S; Ueno S; Ushida H; Piao CH; Kondo M; Terasaki H
Jpn J Ophthalmol; 2014 May; 58(3):232-6. PubMed ID: 24668132
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
3. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
Park SP; Ahn JK
Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
[TBL] [Abstract][Full Text] [Related]
4. Aqueous vascular endothelial growth factor and endothelin-1 levels in branch retinal vein occlusion associated with normal tension glaucoma.
Sin BH; Song BJ; Park SP
J Glaucoma; 2013 Feb; 22(2):104-9. PubMed ID: 21946550
[TBL] [Abstract][Full Text] [Related]
5. Flicker electroretinograms before and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion.
Yasuda S; Kachi S; Ueno S; Piao CH; Terasaki H
Acta Ophthalmol; 2015 Sep; 93(6):e465-8. PubMed ID: 25597703
[TBL] [Abstract][Full Text] [Related]
6. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
7. Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes.
Yasuda S; Kachi S; Kondo M; Ushida H; Uetani R; Terui T; Piao CH; Terasaki H
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5737-42. PubMed ID: 21642626
[TBL] [Abstract][Full Text] [Related]
8. POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
Noma H; Mimura T; Yasuda K; Shimura M
Retina; 2016 Sep; 36(9):1718-25. PubMed ID: 26866529
[TBL] [Abstract][Full Text] [Related]
9. Aqueous Angiopoietin-Like 4 Levels Correlate With Nonperfusion Area and Macular Edema in Branch Retinal Vein Occlusion.
Kim JH; Shin JP; Kim IT; Park DH
Invest Ophthalmol Vis Sci; 2016 Jan; 57(1):6-11. PubMed ID: 26746013
[TBL] [Abstract][Full Text] [Related]
10. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion.
Koss MJ; Pfister M; Rothweiler F; Michaelis M; Cinatl J; Schubert R; Koch FH
Acta Ophthalmol; 2012 Mar; 90(2):e98-e103. PubMed ID: 22066978
[TBL] [Abstract][Full Text] [Related]
12. Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion.
Gardašević Topčić I; Šuštar M; Brecelj J; Hawlina M; Jaki Mekjavić P
Doc Ophthalmol; 2014 Aug; 129(1):27-38. PubMed ID: 24906869
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
[TBL] [Abstract][Full Text] [Related]
15. Higher Aqueous Levels of Resistin and Lipocalin-2 Indicated Worse Visual Improvement following anti-VEGF Therapy in Patients with Retinal Vein Occlusion.
Luo Y; Wan J; Luo C; Liu H; Zhou Y; Chen J; Duan Y; Ning X; Zhou Z; Wang K; Li J; Xu H; Chen Z
Curr Eye Res; 2021 Jun; 46(6):845-854. PubMed ID: 33103481
[TBL] [Abstract][Full Text] [Related]
16. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
19. Significant Correlation between Retinal Venous Tortuosity and Aqueous Vascular Endothelial Growth Factor Concentration in Eyes with Central Retinal Vein Occlusion.
Yasuda S; Kachi S; Kondo M; Ueno S; Kaneko H; Terasaki H
PLoS One; 2015; 10(7):e0134267. PubMed ID: 26214803
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.
Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
